OrbiMed, an investment firm focused on the healthcare sector, announced the closing of its second Israel-focused venture capital fund, OrbiMed Israel Partners II, LP, with approximately $307 million in capital commitments. Investors in the fund include several of the world’s largest healthcare companies, in addition to dozens of institutional investors and family offices.

Consistent with its predecessor fund, OrbiMed Israel Partners II will target all stages and sectors of the healthcare industry, with a focus on biopharmaceuticals, digital health, medical devices and diagnostics companies in Israel. The fund is targeting to invest in approximately 20 portfolio companies. Where appropriate, Israel Partners II may co-invest with OrbiMed’s global private equity team, leveraging the full financial and strategic resources of OrbiMed’s 100+ team members and $15 billion global investment platform.

“Israel is a compelling locus of life sciences innovation, on par with top regions in the U.S. and Europe,” said Jonathan Silverstein, co-head of OrbiMed’s global private equity effort. “With this fund we will further accelerate our investment pace in Israel and help nurture local innovations into leading healthcare companies.”

“Our new fund builds on OrbiMed’s strong 16-year track record of investing in Israel,” said Dr. Nissim Darvish, a senior managing director of OrbiMed. “With a fund of this size, OrbiMed is well-positioned to be a significant partner to entrepreneurs, research institutions and life sciences companies here in Israel.”

OrbiMed’s Israel office was opened in 2010, and is led by Dr. Nissim Darvish, Erez Chimovits and Anat Naschitz.